This company seems to have been delisted
Reason: Merged with Ayala Pharmaceuticals
Source: https://ir.ayalapharma.com/news-releases/news-release-details/advaxis-and-ayala-pharmaceuticals-complete-merger
Reason: Merged with Ayala Pharmaceuticals
Source: https://ir.ayalapharma.com/news-releases/news-release-details/advaxis-and-ayala-pharmaceuticals-complete-merger
Advaxis
ADXS
₹2.60
Share price
0.00%
Change (1 day)
-94.71%
Change (1 year)
Categories
Revenue for Advaxis (ADXS)
Revenue in 2023 (TTM): ₹9.42 Million
According to Advaxis's latest financial reports the company's current revenue (TTM 
) is ₹9.87 Million. In 2022 the company made a revenue of ₹57.26 Million a decrease over the revenue in the year 2021 that were of ₹0.26 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Advaxis from 2019 to 2023
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2023 (TTM) | ₹9.42 M | -83.54% |
| 2022 | ₹57.26 M | -78.06% |
| 2021 | ₹0.26 B | -3.77% |
| 2020 | ₹0.27 B | 62.93% |
| 2019 | ₹0.16 B |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 | ₹18.86 M | 91.01% | 🇺🇸 USA |
 | ₹0.16 B | 1,576.32% | 🇺🇸 USA |
 | ₹22.07 B | 223,485.96% | 🇺🇸 USA |